Dr. David Schlaes

Nabriva, an antibiotic biotech, recently announced that they were winding down its operations. While this is sad, it may not be so much a market failure problem in this particular case.
The U.S. dithers, Europe ponders and the extinction of life-saving antibiotics continues apace.
Former vice president of infectious disease research at Wyeth and ACSH advisor Dr. David Shlaes knows a thing or two about dealing with the FDA, and its misguided policies regarding approval of new antibiotics.